sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease
sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease
复制标题
中国脂肪肝患者sTRAIL水平及TRAIL基因多态性
DOI：
10.1007/s00251-009-0389-4
复制
发表时间：
2009-08-01
期刊：
影响因子：
3.2
通讯作者：
Gao, Lifen
中科院分区：
文献类型：
--
作者：
Yan, Xiaohua;Xu, Liyun;Gao, Lifen
肿瘤坏死因子（TNF）相关凋亡诱导配体（TRAIL）是TNF超家族的成员，已被确定为脂肪肝病（FLD）的新型介体。我们研究的目的是进一步研究TRAIL与FLD之间的关系。我们发现，非酒精FLD（NAFLD）患者的可溶性步道（strail）浓度明显高于对照组的浓度，并且链球水平与NAFLD患者的甘油三酸酯浓度呈正相关。我们的结果还表明，1525/1595的TRAIL的AA/TT基因型导致FLD攻击的风险较低，而在中国人口中，NAFLD患者的脂肪变性较低。这项研究提供了一种测试FLD易感性的方法，并可能有助于诊断FLD。此外，我们发现1525G/A和1595C/T位点在中国人口中处于完全连锁状态。这可能表明具有高遗传频率的单倍型。
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily, and has been identified as a novel mediator of fatty liver disease (FLD). The aim of our study was to further investigate the relationship between TRAIL and FLD. We found that soluble TRAIL (sTRAIL) concentrations in non-alcoholic FLD (NAFLD) patients were significantly higher than those of controls, and that sTRAIL levels positively correlated with triglyceride concentrations in NAFLD patients. Our results also indicated that the AA/TT genotypes of TRAIL at 1525/1595 engendered a lower risk of FLD attack and a less severe form of steatosis for NAFLD patients in Chinese population. This study provides a means to test for susceptibility to FLD and may assist in the diagnosis of FLD. In addition, we found that 1525G/A and 1595C/T sites were in complete linkage disequilibrium in Chinese population. This might indicate a haplotype with high genetic frequency of TRAIL.